SOAT1 and chronic kidney disease: Finally, we evaluated the translational potential of our study in treating CKD‐associated plaque vulnerability using newly identified STING inhibitors, C‐176 and its derivate H‐151[25] or a JAK‐STAT inhibitor, ruxolitinib (RUX).